Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies

NCT00811993 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00811993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00811993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2009
Completion date
December 31, 2012
Enrollment
104 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms